These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29061170)

  • 1. Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).
    Schernthaner G; Lehmann R; Prázný M; Czupryniak L; Ducena K; Fasching P; Janež A; Karasik A; Kempler P; Martinka E; Shestakova MV; Duvnjak LS; Tankova T
    Cardiovasc Diabetol; 2017 Oct; 16(1):137. PubMed ID: 29061170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
    Schnell O; Standl E; Catrinoiu D; Itzhak B; Lalic N; Rahelic D; Skrha J; Valensi P; Ceriello A
    Cardiovasc Diabetol; 2019 Mar; 18(1):30. PubMed ID: 30857522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
    Schnell O; Standl E; Catrinoiu D; Genovese S; Lalic N; Lalic K; Skrha J; Valensi P; Ceriello A
    Cardiovasc Diabetol; 2018 Feb; 17(1):30. PubMed ID: 29458368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.
    Schnell O; Battelino T; Bergenstal R; Birkenfeld AL; Ceriello A; Cheng A; Davies M; Edelman S; Forst T; Giorgino F; Green J; Groop PH; Hadjadj S; J L Heerspink H; Hompesch M; Izthak B; Ji L; Kanumilli N; Mankovsky B; Mathieu C; Miszon M; Mustafa R; Nauck M; Pecoits-Filho R; Pettus J; Ranta K; Rodbard HW; Rossing P; Ryden L; Schumm-Draeger PM; Solomon SD; Škrha J; Topsever P; Vilsbøll T; Wilding J; Standl E
    Cardiovasc Diabetol; 2023 Mar; 22(1):59. PubMed ID: 36927451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register.
    Eliasson B; Ekelund J; Holmberg CN; Wolden ML; Matthiessen KS; James S
    Eur J Prev Cardiol; 2023 May; 30(7):546-551. PubMed ID: 36567502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.
    Davies MJ; Drexel H; Jornayvaz FR; Pataky Z; Seferović PM; Wanner C
    Cardiovasc Diabetol; 2022 Aug; 21(1):144. PubMed ID: 35927730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
    Schnell O; Standl E; Catrinoiu D; Genovese S; Lalic N; Skra J; Valensi P; Ceriello A
    Cardiovasc Diabetol; 2016 Feb; 15():33. PubMed ID: 26892706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
    Handelsman Y; Anderson JE; Bakris GL; Ballantyne CM; Beckman JA; Bhatt DL; Bloomgarden ZT; Bozkurt B; Budoff MJ; Butler J; Dagogo-Jack S; de Boer IH; DeFronzo RA; Eckel RH; Einhorn D; Fonseca VA; Green JB; Grunberger G; Guerin C; Inzucchi SE; Jellinger PS; Kosiborod MN; Kushner P; Lepor N; Mende CW; Michos ED; Plutzky J; Taub PR; Umpierrez GE; Vaduganathan M; Weir MR
    J Diabetes Complications; 2022 Feb; 36(2):108101. PubMed ID: 34922811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.
    Pintat S; Fenici P; Hammar N; Ji L; Khunti K; Medina J; Tang F; Wittbrodt E; Surmont F
    BMJ Open Diabetes Res Care; 2019; 7(1):e000627. PubMed ID: 31114700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.
    Schnell O; Cos X; Cosentino F; Forst T; Giorgino F; Heersprink HJL; Kosiborod M; Wanner C; Standl E
    Cardiovasc Diabetol; 2021 Mar; 20(1):75. PubMed ID: 33789663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.
    Schnell O; Barnard-Kelly K; Battelino T; Ceriello A; Larsson HE; Fernández-Fernández B; Forst T; Frias JP; Gavin JR; Giorgino F; Groop PH; Heerspink HJL; Herzig S; Hummel M; Huntley G; Ibrahim M; Itzhak B; Jacob S; Ji L; Kosiborod M; Lalic N; Macieira S; Malik RA; Mankovsky B; Marx N; Mathieu C; Müller TD; Ray K; Rodbard HW; Rossing P; Rydén L; Schumm-Draeger PM; Schwarz P; Škrha J; Snoek F; Tacke F; Taylor B; Jeppesen BT; Tesfaye S; Topsever P; Vilsbøll T; Yu X; Standl E
    Cardiovasc Diabetol; 2024 Mar; 23(1):104. PubMed ID: 38504284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes.
    Sciannameo V; Berchialla P; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2021 May; 20(1):103. PubMed ID: 33971880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
    J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK.
    Bain SC; Bakhai A; Evans M; Green A; Menown I; Strain WD
    Diabet Med; 2019 Sep; 36(9):1063-1071. PubMed ID: 31254356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiorenal disease management in type 2 diabetes: An expert consensus.
    Mohan V; Singh AK; Zargar AH; Almeida A; Bhalla AK; Mohan JC; Dalal J; Sahay M; Mohanan PP; Maitra S; Ghosh S; Jeloka T; Kaul U; Sakhuja V; Das MK
    Diabetes Metab Syndr; 2022 Dec; 16(12):102661. PubMed ID: 36375366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.